Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2019 1
2021 2
2022 2
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Usmani SZ, et al. Nat Med. 2025 Apr;31(4):1195-1202. doi: 10.1038/s41591-024-03485-7. Epub 2025 Feb 5. Nat Med. 2025. PMID: 39910273 Free PMC article. Clinical Trial.
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.
Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallón de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Baruch EN, et al. Nature. 2025 Oct;646(8084):462-473. doi: 10.1038/s41586-025-09370-8. Epub 2025 Aug 20. Nature. 2025. PMID: 40836096 Free PMC article.
Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality.
Stamatakis E, Biswas RK, Koemel NA, Sabag A, Pulsford R, Atkin AJ, Stathi A, Cheng S, Thøgersen-Ntoumani C, Blodgett JM, Bauman A, Celis-Morales C, Hamer M, Gill JMR, Ahmadi MN. Stamatakis E, et al. Circulation. 2025 Apr 15;151(15):1063-1075. doi: 10.1161/CIRCULATIONAHA.124.072253. Epub 2025 Apr 14. Circulation. 2025. PMID: 40228066 Free PMC article.
Self-assembled Arginine-Glycine-Aspartic Acid Mimic Peptide Hydrogels as Multifunctional Biomaterials for Wound Healing.
Ahmadi Z, Jha D, Yadav S, Singh AP, Singh VP, Gautam HK, Sharma AK, Kumar P. Ahmadi Z, et al. ACS Appl Mater Interfaces. 2024 Dec 11;16(49):67302-67320. doi: 10.1021/acsami.4c14686. Epub 2024 Nov 29. ACS Appl Mater Interfaces. 2024. PMID: 39613718
In our previous work, we synthesized an integrin-binding cell adhesive M(NH2) {Fmoc-FFbetaAR(K)betaA-NH(2) consisting of an RGD mimic, [R(K)], with an amide terminus}, M(OH) {Fmoc-FFbetaAR(K)betaA-OH consisting of an RGD mimic, [R(K)], with acid terminus}, and M(R) …
In our previous work, we synthesized an integrin-binding cell adhesive M(NH2) {Fmoc-FFbetaAR(K)betaA-NH(2) consisting of an RGD mimic, [R(K) …
Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry.
Dundas J, Leipsic J, Fairbairn T, Ng N, Sussman V, Guez I, Rosenblatt R, Hurwitz Koweek LM, Douglas PS, Rabbat M, Pontone G, Chinnaiyan K, de Bruyne B, Bax JJ, Amano T, Nieman K, Rogers C, Kitabata H, Sand NPR, Kawasaki T, Mullen S, Huey W, Matsuo H, Patel MR, Norgaard BL, Ahmadi A, Tzimas G. Dundas J, et al. Circ Cardiovasc Imaging. 2024 Mar;17(3):e016143. doi: 10.1161/CIRCIMAGING.123.016143. Epub 2024 Mar 12. Circ Cardiovasc Imaging. 2024. PMID: 38469689
An injectable self-assembling hydrogel based on RGD peptidomimetic β-sheets as multifunctional biomaterials.
Ahmadi Z, Yadav S, Kar AK, Jha D, Gautam HK, Patnaik S, Kumar P, Sharma AK. Ahmadi Z, et al. Biomater Adv. 2022 Feb;133:112633. doi: 10.1016/j.msec.2021.112633. Epub 2021 Dec 27. Biomater Adv. 2022. PMID: 35527136
Besides, a multifunctional material with inherent antimicrobial ability would help in invigorating the practical tissue engineering applications. Here, we report novel modified RGD (M(R)) and RGD mimic [R(K)] peptides (M(OH) and M(NH)(2)) which were synthesized post …
Besides, a multifunctional material with inherent antimicrobial ability would help in invigorating the practical tissue engineering applicat …
The prevalence, comorbidity and socio-demographic factors of depressive disorder among Iranian children and adolescents: To identify the main predictors of depression.
Mohammadi MR, Alavi SS, Ahmadi N, Khaleghi A, Kamali K, Ahmadi A, Hooshyari Z, Mohamadian F, Jaberghaderi N, Nazaribadie M, Sajedi Z, Farshidfar Z, Kaviani N, Davasazirani R, Shahbakhsh AJ, Rad MR, Shahbazi K, Khodaverdloo RR, Tehrani LN, Nasiri M, Naderi F, Kiani A, Chegeni M, Hashemi Nasab SM, Ghaneian M, Parsamehr H, Nilforoushan N, Amiri S, Fooladi MF, Mohammadzadeh S, Ahmadipour A, Sarraf N, Hojjat SK, Nadermohammadi M, Mostafavi SA, Zarafshan H, Salmanian M, Shakiba A, Ashoori S. Mohammadi MR, et al. J Affect Disord. 2019 Mar 15;247:1-10. doi: 10.1016/j.jad.2019.01.005. Epub 2019 Jan 5. J Affect Disord. 2019. PMID: 30640024
11 results